Cargando…

Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway

BACKGROUND: Eukaryotic translation initiation factor 6 (eIF6), also known as integrin β4 binding protein, is involved in ribosome formation and mRNA translation, acting as an anti-association factor. It is also essential for the growth and reproduction of cells, including tumor cells. Yet, its role...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zechen, Chu, Weiming, Zheng, Yang, Wang, Chao, Yang, Yuemei, Xu, Teng, Yang, Xueming, Zhang, Wei, Ding, Xu, Li, Gang, Zhang, Hongchuang, Zhou, Junbo, Ye, Jinhai, Wu, Heming, Song, Xiaomeng, Wu, Yunong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684100/
https://www.ncbi.nlm.nih.gov/pubmed/34922580
http://dx.doi.org/10.1186/s12964-021-00800-4
_version_ 1784617547836948480
author Zhao, Zechen
Chu, Weiming
Zheng, Yang
Wang, Chao
Yang, Yuemei
Xu, Teng
Yang, Xueming
Zhang, Wei
Ding, Xu
Li, Gang
Zhang, Hongchuang
Zhou, Junbo
Ye, Jinhai
Wu, Heming
Song, Xiaomeng
Wu, Yunong
author_facet Zhao, Zechen
Chu, Weiming
Zheng, Yang
Wang, Chao
Yang, Yuemei
Xu, Teng
Yang, Xueming
Zhang, Wei
Ding, Xu
Li, Gang
Zhang, Hongchuang
Zhou, Junbo
Ye, Jinhai
Wu, Heming
Song, Xiaomeng
Wu, Yunong
author_sort Zhao, Zechen
collection PubMed
description BACKGROUND: Eukaryotic translation initiation factor 6 (eIF6), also known as integrin β4 binding protein, is involved in ribosome formation and mRNA translation, acting as an anti-association factor. It is also essential for the growth and reproduction of cells, including tumor cells. Yet, its role in oral squamous cell carcinoma (OSCC) remains unclear. METHODS: The expression characteristics of eIF6 in 233 samples were comprehensively analyzed by immunohistochemical staining (IHC). Effects of eIF6 over-expression and knockdown on cell proliferation, migration and invasion were determined by CCK-8, wound healing and Transwell assays. Western blot, immunofluorescence (IF) and co-immunoprecipitation (co-IP) were performed for mechanical verification. RESULTS: We found that cytoplasmic eIF6 was abnormally highly expressed in OSCC tissues, and its expression was associated with tumor size and the clinical grade. Amplification of eIF6 promoted the growth, migration and invasion capabilities of OSCC cell lines in vitro and tumor growth in vivo. Through Western blot analysis, we further discovered that eIF6 significantly promotes epithelial-mesenchymal transformation (EMT) in OSCC cells, while depletion of eIF6 can reverse this process. Mechanistically, eIF6 promoted tumor progression by activating the AKT signaling pathway. By performing co-immunoprecipitation, we discovered a direct interaction between endogenous eIF6 and AKT protein in the cytoplasm. CONCLUSION: These results demonstrated that eIF6 could be a new therapeutic target in OSCC, thus providing a new basis for the prognosis of OSCC patients in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-021-00800-4.
format Online
Article
Text
id pubmed-8684100
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86841002021-12-20 Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway Zhao, Zechen Chu, Weiming Zheng, Yang Wang, Chao Yang, Yuemei Xu, Teng Yang, Xueming Zhang, Wei Ding, Xu Li, Gang Zhang, Hongchuang Zhou, Junbo Ye, Jinhai Wu, Heming Song, Xiaomeng Wu, Yunong Cell Commun Signal Research BACKGROUND: Eukaryotic translation initiation factor 6 (eIF6), also known as integrin β4 binding protein, is involved in ribosome formation and mRNA translation, acting as an anti-association factor. It is also essential for the growth and reproduction of cells, including tumor cells. Yet, its role in oral squamous cell carcinoma (OSCC) remains unclear. METHODS: The expression characteristics of eIF6 in 233 samples were comprehensively analyzed by immunohistochemical staining (IHC). Effects of eIF6 over-expression and knockdown on cell proliferation, migration and invasion were determined by CCK-8, wound healing and Transwell assays. Western blot, immunofluorescence (IF) and co-immunoprecipitation (co-IP) were performed for mechanical verification. RESULTS: We found that cytoplasmic eIF6 was abnormally highly expressed in OSCC tissues, and its expression was associated with tumor size and the clinical grade. Amplification of eIF6 promoted the growth, migration and invasion capabilities of OSCC cell lines in vitro and tumor growth in vivo. Through Western blot analysis, we further discovered that eIF6 significantly promotes epithelial-mesenchymal transformation (EMT) in OSCC cells, while depletion of eIF6 can reverse this process. Mechanistically, eIF6 promoted tumor progression by activating the AKT signaling pathway. By performing co-immunoprecipitation, we discovered a direct interaction between endogenous eIF6 and AKT protein in the cytoplasm. CONCLUSION: These results demonstrated that eIF6 could be a new therapeutic target in OSCC, thus providing a new basis for the prognosis of OSCC patients in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-021-00800-4. BioMed Central 2021-12-18 /pmc/articles/PMC8684100/ /pubmed/34922580 http://dx.doi.org/10.1186/s12964-021-00800-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhao, Zechen
Chu, Weiming
Zheng, Yang
Wang, Chao
Yang, Yuemei
Xu, Teng
Yang, Xueming
Zhang, Wei
Ding, Xu
Li, Gang
Zhang, Hongchuang
Zhou, Junbo
Ye, Jinhai
Wu, Heming
Song, Xiaomeng
Wu, Yunong
Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway
title Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway
title_full Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway
title_fullStr Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway
title_full_unstemmed Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway
title_short Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway
title_sort cytoplasmic eif6 promotes oscc malignant behavior through akt pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684100/
https://www.ncbi.nlm.nih.gov/pubmed/34922580
http://dx.doi.org/10.1186/s12964-021-00800-4
work_keys_str_mv AT zhaozechen cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT chuweiming cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT zhengyang cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT wangchao cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT yangyuemei cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT xuteng cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT yangxueming cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT zhangwei cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT dingxu cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT ligang cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT zhanghongchuang cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT zhoujunbo cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT yejinhai cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT wuheming cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT songxiaomeng cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway
AT wuyunong cytoplasmiceif6promotesosccmalignantbehaviorthroughaktpathway